Literature DB >> 17530732

Thyronamines inhibit plasma membrane and vesicular monoamine transport.

Aaron N Snead1, Magda S Santos, Rebecca P Seal, Motonori Miyakawa, Robert H Edwards, Thomas S Scanlan.   

Abstract

Thyroid hormone has long been known to have important transcriptional regulatory activities. Recently, however, the presence of endogenous derivatives of thyroid hormone, thyronamines, has been reported in various mammalian tissues. These derivatives have potent in vitro activity with a class of orphan G-protein-coupled receptors, the trace amine-associated receptors, and profound in vivo effects when administered to mice. We report here a novel neuromodulatory role for thyronamines. In synaptosomal preparations and heterologous expression systems, thyronamines act as specific dopamine and norepinephrine reuptake inhibitors. Thyronamines also inhibit the transport of monoamines into synaptic vesicles. These observations expand the nontranscriptional role of thyroid hormone derivatives and may help to explain the pharmacological effects of thyronamines in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530732     DOI: 10.1021/cb700057b

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  25 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  Avenues for the development of therapeutics that target trace amine associated receptor 1 (TAAR1).

Authors:  Gregory M Miller
Journal:  J Med Chem       Date:  2012-01-20       Impact factor: 7.446

3.  Mitochondrial F(0) F(1) -ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone.

Authors:  S Cumero; F Fogolari; R Domenis; R Zucchi; I Mavelli; S Contessi
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

4.  Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine.

Authors:  Alexandra G Ianculescu; Edith C H Friesema; Theo J Visser; Kathleen M Giacomini; Thomas S Scanlan
Journal:  Mol Biosyst       Date:  2010-03-31

Review 5.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

6.  Identification and characterization of 3-iodothyronamine intracellular transport.

Authors:  Alexandra G Ianculescu; Kathleen M Giacomini; Thomas S Scanlan
Journal:  Endocrinology       Date:  2008-12-12       Impact factor: 4.736

7.  Validation of a liquid chromatography-tandem mass spectrometry method to enable quantification of 3-iodothyronamine from serum.

Authors:  Andrea E DeBarber; Travis Geraci; Vincent P Colasurdo; Sarah A Hackenmueller; Thomas S Scanlan
Journal:  J Chromatogr A       Date:  2008-09-12       Impact factor: 4.759

8.  Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold.

Authors:  Maria Elena Manni; Gaetano De Siena; Alessandro Saba; Maja Marchini; Elisa Landucci; Elisabetta Gerace; Marina Zazzeri; Claudia Musilli; Domenico Pellegrini-Giampietro; Rosanna Matucci; Riccardo Zucchi; Laura Raimondi
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 9.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

10.  Effects of acute microinjections of the thyroid hormone derivative 3-iodothyronamine to the preoptic region of adult male rats on sleep, thermoregulation and motor activity.

Authors:  Thomas D James; Steven X Moffett; Thomas S Scanlan; Joseph V Martin
Journal:  Horm Behav       Date:  2013-05-20       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.